AdAlta To Raise Funds To Take Shark-Derived Fibrosis Candidate Into Clinic
Executive Summary
Australian biotech company AdAlta develops protein therapeutics based on shark antibodies, much the same way as Ablynx and others use camelid antibodies. It has just applied to raise an IPO on the Australian Securities Exchange [ASX] to fund clinical studies with its lead compound AD-114 which shows promise in treating fibrosis.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.